EUVIMEDEUVIMED entdecken
KommentarOpen Access

Pridopidine in Amyotrophic Lateral Sclerosis

Writing Committee for the HEALEY ALS Platform Trial, Jeremy M Shefner, Björn Oskarsson, Eric A Macklin, Lori B Chibnik, Melanie Quintana, Benjamin R Saville, Michelle A Detry, Matteo Vestrucci, Joe Marion, Anna McGlothlin, Terry Heiman-Patterson und 48 weitere

JAMA · 01.04.2025 · 333 (13) · 1128

DOI: 10.1001/jama.2024.26429 ↗

Kurz gefasst

Kommentar in der Zeitschrift JAMA, erschienen am 01.04.2025. Verfasst von Writing Committee for the HEALEY ALS Platform Trial und 59 weiteren Autor:innen. Beteiligte Einrichtung: Barrow Neurological Institute, Phoenix, Arizona. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Amyotrophic lateral sclerosis (ALS) is a fatal disease. The sigma-1 (σ1) receptor emerged as a target for intervention.

Objective

To determine the effects of pridopidine, a σ1-receptor agonist, in ALS. Design, Settings, and Participants Pridopidine was tested as a regimen of the HEALEY ALS Platform Trial, a phase 2/3, multicenter, randomized, double-blind, platform trial. The study was conducted at 54 sites in the US from January 2021 to July 2022 (final follow-up, July 14, 2022). A total of 163 participants with ALS were randomized to receive pridopidine or placebo. An additional 122 concurrently randomized participants were assigned to receive placebo in other regimens and included in the analyses.

Interventions

Eligible participants were randomized 3:1 to receive oral pridopidine 45 mg twice daily (n = 121) or matching oral placebo (n = 42) for a planned duration of 24 weeks. Main Outcomes and Measures The primary efficacy outcome was change from baseline through week 24 in ALS disease severity, analyzed using a bayesian shared parameter model, which has components for function (Revised Amyotrophic Lateral Sclerosis Functional Rating Scale [ALSFRS-R]) and survival that were linked through an integrated estimate of treatment-dependent disease slowing across these 2 components. This was denoted as the disease rate ratio (DRR), with DRR less than 1 indicating a slowing in disease progression on pridopidine relative to placebo. There were 5 key secondary end points: time to 2-point or greater reduction in ALSFRS-R total score among participants with bulbar dysfunction at baseline, rate of decline in slow vital capacity among participants with bulbar dysfunction at baseline, percentage of participants with no worsening in the ALSFRS-R bulbar domain score, time to 1-point or greater change in the ALSFRS-R bulbar domain score, and time to death or permanent assisted ventilation.

Results

Among 162 patients (mean age, 57.5 years; 35% female) who were randomized to receive the pridopidine regimen and included in the primary efficacy analysis, 136 (84%) completed the trial. In the primary analysis comparing pridopidine vs the combined placebo groups, there was no significant difference between pridopidine and placebo in the primary end point (DRR, 0.99 [95% credible interval, 0.80-1.21]; probability of DRR <1, 0.55) and no differences were seen in the components of ALSFRS-R or survival. There was no benefit of pridopidine on the secondary end points. In the safety dataset (pridopidine, n = 121; placebo, n = 163), the most common adverse events were falls (28.1% vs 29.3%, respectively) and muscular weakness (24.0% vs 31.7%, respectively). Conclusions and Relevance In this 24-week study, pridopidine did not impact the progression of ALS. Trial Registration ClinicalTrials.gov Identifiers: NCT04297683 , NCT04615923

Autor:innen und Institutionen

  • Barrow Neurological Institute, Phoenix, Arizona.
  • Mayo Clinic Jacksonville, Jacksonville, Florida.
  • Sean M. Healey and AMG Center for ALS and the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston.
  • Berry Consultants, Austin, Texas.
  • Temple University, Philadelphia, Pennsylvania.
  • Columbia University, New York, New York.

Zitieren

APA

Writing Committee for the HEALEY ALS Platform Trial, Shefner, J. M., Oskarsson, B., Macklin, E. A., Chibnik, L. B., Quintana, M., Saville, B. R., Detry, M. A., Vestrucci, M., Marion, J., McGlothlin, A., Heiman-Patterson, T., Chase, M., Pothier, L., Harkey, B. A., Yu, H., Sherman, A. V., Hall, M., Kittle, G., …, & Kasarskis, E. J. (2025). Pridopidine in Amyotrophic Lateral Sclerosis. JAMA, 333(13), 1128. https://doi.org/10.1001/jama.2024.26429

Vancouver

Writing Committee for the HEALEY ALS Platform Trial, Shefner JM, Oskarsson B, Macklin EA, Chibnik LB, Quintana M, et al. Pridopidine in Amyotrophic Lateral Sclerosis. JAMA. 2025;333(13):1128. doi:10.1001/jama.2024.26429

BibTeX
@article{WritingCommitteefortheHEALEYALSPlatformTrial2025,
  author = {Writing Committee for the HEALEY ALS Platform Trial, Writing Committee for the HEALEY ALS Platform Trial and Shefner, Jeremy M and Oskarsson, Björn and Macklin, Eric A and Chibnik, Lori B and Quintana, Melanie and Saville, Benjamin R and Detry, Michelle A and Vestrucci, Matteo and Marion, Joe and McGlothlin, Anna and Heiman-Patterson, Terry and Chase, Marianne and Pothier, Lindsay and Harkey, Brittney A and Yu, Hong and Sherman, Alexander V and Hall, Meghan and Kittle, Gale and Berry, James D and Babu, Suma and Andrews, Jinsy and D'Agostino, Derek and Tustison, Eric and Scirocco, Erica and Giacomelli, Elisa and Alameda, Gustavo and Locatelli, Eduardo and Ho, Doreen and Quick, Adam and Ajroud-Driss, Senda and Katz, Jonathan and Heitzman, Daragh and Appel, Stanley H and Shroff, Sheetal and Felice, Kevin and Maragakis, Nicholas J and Simmons, Zachary and Miller, Timothy M and Olney, Nicholas and Weiss, Michael D and Goutman, Stephen A and Fernandes, Joseph Americo and Jawdat, Omar and Owegi, Margaret Ayo and Foster, Laura A and Vu, Tuan and Ilieva, Hristelina and Newman, Daniel S and Arcila-Londono, Ximena and Jackson, Carlayne E and Ladha, Shafeeq and Caress, James B and Swenson, Andrea and Peltier, Amanda and Lewis, Richard A and Fee, Dominic and Elliott, Matthew and Bedlack, Richard and Kasarskis, Edward J},
  title = {Pridopidine in Amyotrophic Lateral Sclerosis},
  journal = {JAMA},
  year = {2025},
  volume = {333},
  number = {13},
  pages = {1128},
  doi = {10.1001/jama.2024.26429}
}
Kostenlos starten →